Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $0.7652W HIGH $3.31
Volume
540.98 K
Value Traded
1.05 M
Short % Float
16.86%
-5.36%Week
+0.95%1 Month
-20.3%3 Month
-32.91%6 Month
-78.68%5 Year
-99.89%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
82.46 M
EPS (TTM)
-0.51
P/E Ratio
-
Ent. Value
47.94 M
Total Shares
77.80 M
Float Shares
73.00 M
Insiders
6.17%
Institutions
21.93%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
CRDF Catalyst Timeline
Dated clinical, regulatory and corporate events for Cardiff Oncology, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Cardiff Oncology, Inc.
581Total events
3Upcoming
82Tier-1 (high impact)
2012 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲Legal / SettlementOnvansertibCorporate
Cardiff and NMS reach settlement and amend 2017 Exclusive License Agreement over onvansertib rights
cancersource ↗
▲Oral PresentationOnvansertibPresentation
Positive Phase 2 CRDF-004 data presented in oral session at ASCO
first-line RAS-mutated metastatic colorectal cancersource ↗
▲End Of Phase 2 MeetingOnvansertibFDA Meeting
Successful End-of-Phase 2 meeting with FDA
first-line RAS-mutated metastatic colorectal cancersource ↗
▼Equity OfferingCorporate
Announced $10 million registered direct offering of common stock and warrants
◆Oral PresentationPresentation
Cardiff Oncology management to present at Jefferies Global Healthcare Conference
◆Quarterly UpdateOnvansertibCorporate
Investor webcast to review updated CRDF-004 data
first-line RAS-mutated metastatic colorectal cancersource ↗
◆Quarterly UpdateCorporate
Investor webcast to review Phase 2 data and registrational study plans
◆Oral PresentationOnvansertibPresentation
Rapid oral presentation of updated Phase 2 data of onvansertib in first-line RAS-mutated mCRC at ASCO 2026
first-line RAS-mutated metastatic colorectal cancer (mCRC)source ↗
▲End Of Phase 2 MeetingOnvansertibFDA Meeting
Successful End-of-Phase 2 meeting with FDA; alignment on registrational trial design
first-line RAS-mutated metastatic colorectal cancersource ↗
▲Oral PresentationOnvansertibPresentation
Positive Phase 2 CRDF-004 data presented in oral session at ASCO
first-line RAS-mutated metastatic colorectal cancersource ↗
◆Oral PresentationOnvansertibPresentation
Rapid oral presentation of updated CRDF-004 data at ASCO 2026
first-line RAS-mutated metastatic colorectal cancersource ↗
◆AbstractOnvansertibPresentation
Abstract for CRDF-004 trial available on ASCO website
first-line RAS-mutated metastatic colorectal cancer (mCRC)source ↗
◆Oral PresentationOnvansertibPresentation
KOL webinar discussing onvansertib single-agent activity in CMML
chronic myelomonocytic leukemia (CMML)source ↗
◆Poster PresentationOnvansertibPresentation
Poster presentation of preclinical data on onvansertib + T-DXd at AACR 2026
HER2-low breast cancersource ↗
▲End Of Phase 2 MeetingOnvansertibFDA Meeting
Successful End-of-Phase 2 meeting with FDA; aligned on Phase 3 design
first-line RAS-mutated metastatic colorectal cancersource ↗
▲Preclinical PoCOnvansertibPreclinical
Preclinical data at AACR 2026: onvansertib enhances T-DXd activity in HER2-low breast cancer models
HER2-low breast cancersource ↗
▲Management ChangeCorporate
Appointment of Mani Mohindru as President and CEO, Josh Muntner as CFO, Ajay Aggarwal as COO
◆Oral PresentationOnvansertibPresentation
KOL webinar discussing onvansertib clinical data and potential in first-line RAS-mutated mCRC
first-line RAS-mutated metastatic colorectal cancersource ↗
◆Oral PresentationPresentation
Oppenheimer 36th Annual Healthcare Life Sciences Conference presentation
▲Topline ReadoutOnvansertibClinical Data
Positive update from Phase 2 CRDF-004 trial: ORR 72.2%, PFS HR 0.37
first-line RAS-mutated metastatic colorectal cancersource ↗
◆Management ChangeCorporate
Mani Mohindru appointed interim CEO; Mark Erlander and James Levine stepped down
▲Topline ReadoutOnvansertibClinical Data
Positive update from randomized Phase 2 trial of onvansertib in first-line RAS-mutated mCRC
first-line RAS-mutated metastatic colorectal cancersource ↗
●Oral PresentationOnvansertibPresentation
Conference call and webcast to discuss positive update
first-line RAS-mutated metastatic colorectal cancersource ↗
▲Topline ReadoutOnvansertibClinical Data
Positive topline data from Phase 2 CRDF-004 trial
first-line RAS-mutated metastatic colorectal cancersource ↗
◆Timing GuidanceOnvansertibPresentation
Update on first-line mCRC program expected by Q1 2026
first-line RAS-mutated metastatic colorectal cancersource ↗
▲End Of Phase 2 MeetingOnvansertibFDA Meeting
Successful End-of-Phase 2 meeting with FDA
first-line RAS-mutated metastatic colorectal cancersource ↗
◆Oral PresentationPresentation
Cardiff Oncology management to present at Sidoti Year-End Virtual Investor Conference
◆Poster PresentationOnvansertibPresentation
Poster presentation of Phase 1 data for onvansertib in CMML at ASH 2025
chronic myelomonocytic leukemia (CMML)source ↗
●Oral PresentationOnvansertibPresentation
Presentation of investigator-sponsored clinical data in CMML at ASH Annual Meeting
chronic myelomonocytic leukemiasource ↗
◆Oral PresentationPresentation
Guggenheim Securities 2nd Annual Healthcare Innovation Conference
▲Topline ReadoutOnvansertibClinical Data
Positive data from ongoing Phase 2 CRDF-004 trial announced
first-line RAS-mutated metastatic colorectal cancersource ↗
◆Oral PresentationPresentation
Noble Capital Markets’ Emerging Growth Virtual Equity Conference Fireside Chat
◆Oral PresentationPresentation
Morgan Stanley 23rd Annual Global Healthcare Conference 1x1 Meetings
◆Topline ReadoutOnvansertibClinical Data
Additional clinical data from CRDF-004 trial to be shared
first-line RAS-mutated metastatic colorectal cancersource ↗
▲Patent GrantedOnvansertibIP / Competition
Second patent issuance from USPTO for treatment of mCRC for bev-naive patients
metastatic colorectal cancer (mCRC) for bev-naive patientssource ↗
◆Timing GuidanceOnvansertibPresentation
Conference call to share updated clinical data from CRDF-004 trial
first-line RAS-mutated mCRCsource ↗
Past FDA Catalysts and PDUFA Decisions
How CRDF actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | Onvansertib | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
D32 / 100
Pipeline Score
$12M
Pipeline Value
Richly Valued
Valuation Signal
1
Drugs Scored
0.1x
rNPV / MCap
Top 62%
Micro Cap(rank 408 of 658)
Percentile Rank
Cardiff Oncology, Inc. faces pipeline headwinds (32/100), with $283M risk-adjusted pipeline value, led by Onvansertib in Metastatic Colorectal Cancer (Phase 2).
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Onvansertib Small moleculeNCT05450965 | Small-cell Lung Cancer | Phase 2 | RECRUITING | 37 | Nov 30, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every CRDF program
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| PACE GARY WDirector | Buy | 687,285 687,285 held | $0.00 | 07/14/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in CRDF
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| COMMODORE CAPITAL LP | 1.2 % (-29.4 %) | 16.91 M | 5.38 M |
CRDF Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How CRDF ranks across every disease it competes in
Competitive Position is a premium feature
See how CRDF ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialCRDF News
CRDF▲ +8.3%on this news
Cardiff Oncology and Nerviano Medical Sciences Amend their 2017 Exclusive License Agreement
Cardiff Oncology and Nerviano Medical Sciences have amended their 2017 Exclusive License Agreement, resolving disputes over the global rights for onvansertib. The settlement includes a mutual release of claims and establishes a collaborative framework for further clinical development. Both companies aim to advance onvansertib into a global Phase 3 study for RAS-mutated metastatic colorectal cancer, highlighting its potential as a treatment option.
Read more →CRDFCardiff Oncology to Participate in September 2026 Conferences
Cardiff Oncology, Inc. announced its participation in two upcoming conferences focused on PLK1 targeted therapy for RAS mutant metastatic colorectal cancer. Dr. Mani Mohindru will present at the 8th Annual RAS-Targeted Drug Development Summit on September 8 and at the H.C. Wainwright 28th Annual Global Investment Conference on September 14. The company aims to address unmet needs in cancer treatment through its lead asset, onvansertib.
Read more →CRDF▼ -5.7%on this news
Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update
Cardiff Oncology has reported positive results from its Phase 2 CRDF-004 trial, which were presented at the ASCO conference. The data supports the advancement of onvansertib in combination with FOLFIRI/bevacizumab for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC). Following a successful End-of-Phase 2 meeting with the FDA, the company is aligned on key program elements.
Read more →CRDF▼ -32.1%on this news
Cardiff Oncology Announces $10 Million Registered Direct Offering
Cardiff Oncology has announced a registered direct offering to raise approximately $10 million by selling shares and warrants. The offering includes participation from company officers and directors. The funds are intended for working capital and corporate purposes, with the closing expected around July 16, 2026, pending customary conditions.
Read more →CRDFCardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting
Cardiff Oncology announced positive results from its Phase 2 trial of onvansertib in RAS-mutated mCRC, showing a 72.2% overall response rate compared to 42.1% for standard-of-care. The trial confirmed the safety and efficacy of the 30 mg dose combined with FOLFIRI/bevacizumab. A registrational Phase 3 trial is planned following FDA alignment.
Read more →CRDFCardiff Oncology to Participate in the Jefferies Global Healthcare Conference 2026
Cardiff Oncology, a clinical-stage biotechnology firm, will present at the Jefferies Global Healthcare Conference from June 2-4, 2026. CEO Mani Mohindru will lead a fireside chat on June 4, discussing their lead asset, onvansertib, which targets PLK1 inhibition in cancer treatment. The company aims to address significant unmet needs in RAS-mutated metastatic colorectal cancer.
Read more →CRDF▼ -22.1%on this newsshared move
Cardiff Oncology to Participate in the Jefferies Global Healthcare Conference
Cardiff Oncology, Inc. will present at the Jefferies Global Healthcare Conference from June 2-4, 2026. CEO Mani Mohindru will participate in a fireside chat on June 4, discussing the company's innovative cancer therapies, particularly their lead asset, onvansertib. This drug is currently in a Phase 2 trial for treating RAS-mutated metastatic colorectal cancer.
Read more →CRDFCardiff Oncology Announces Webcast to Discuss Updated Phase 2 CRDF-004 Data for Onvansertib in First-Line RAS-Mutated mCRC
Cardiff Oncology announced an investor webcast on June 3, 2026, to discuss updated Phase 2 CRDF-004 data for onvansertib in first-line RAS-mutated metastatic colorectal cancer. The data will first be presented at the ASCO Annual Meeting on June 2, 2026. This follows earlier findings indicating onvansertib's effectiveness in improving patient outcomes when combined with standard treatments.
Read more →CRDFCardiff Oncology Reports First Quarter 2026 Results and Provides Business Update Completed successful End-of-Phase 2 meeting with the FDA and selected onvansertib dose and chemotherapy regimen for planned Phase 3 trial
Cardiff Oncology announced its first quarter 2026 results, highlighting a successful End-of-Phase 2 meeting with the FDA regarding the Phase 3 trial design for onvansertib in treating first-line RAS-mutated metastatic colorectal cancer (mCRC). The company reported encouraging outcomes from its Phase 2 CRDF-004 trial, including a high objective response rate and improved progression-free survival. Cardiff is set to present additional data at the upcoming ASCO Annual Meeting, while the company also appointed new executive leadership to support its growth strategy. Financially, Cardiff maintains a robust cash position, enabling operations into early 2027.
Read more →CRDFCardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - April 28, 2026
Cardiff Oncology has granted non-qualified stock options to Dr. Aggarwal as part of his induction as Chief Operating Officer. The grant, totaling 400,000 shares, complies with Nasdaq Listing Rule 5635(c)(4) and has an exercise price of $1.72 per share. The options will vest over four years, contingent on Dr. Aggarwal's continued employment.
Read more →CRDFCardiff Oncology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Cardiff Oncology has granted non-qualified stock options to Dr. Aggarwal, its new COO, as an inducement for his employment. The grant includes 400,000 shares with an exercise price of $1.72 per share. This option vests over four years, reflecting the company's commitment to attract top talent while advancing its cancer treatment initiatives, particularly with its lead asset, onvansertib.
Read more →CRDFCardiff Oncology to Host Key Opinion Leader Discussion on Onvansertib’s Promising Single-Agent Activity
Cardiff Oncology will host a key opinion leader webinar on April 30, 2026, to discuss the promising single-agent activity of onvansertib in chronic myelomonocytic leukemia (CMML). The webinar will feature KOL Mrinal Patnaik from Mayo Clinic, who specializes in hematology and precision genomics. This event aims to share insights from an investigator-initiated trial and enhance understanding of onvansertib's clinical potential.
Read more →CRDF▼ -7.3%on this news
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
Cardiff Oncology announced it will present updated Phase 2 data for onvansertib at the ASCO 2026 Annual Meeting. The trial evaluates onvansertib in combination with standard care for first-line RAS-mutated metastatic colorectal cancer. This presentation underscores the company's commitment to addressing significant unmet needs in cancer treatment.
Read more →CRDF▲ +6.5%on this newsshared move
Cardiff Oncology Presents Preclinical Data on its PLK1 Inhibitor Onvansertib in Combination with a HER2-Targeted ADC at the 2026 AACR Annual Meeting
Cardiff Oncology, Inc. presented promising preclinical data at the 2026 AACR Annual Meeting regarding their PLK1 inhibitor, onvansertib, in combination with the HER2-targeted antibody-drug conjugate, trastuzumab deruxtecan (T-DXd). This combination displayed strong antitumor activity and showed potential in overcoming resistance in HER2-low breast cancer models. Key findings included significant tumor regression rates and enhanced survival, indicating a new treatment avenue for patients resistant to current therapies. The company continues to advance onvansertib through various clinical evaluations across multiple cancer types.
Read more →CRDF▼ -5.4%on this news
Cardiff Oncology Announces Key Leadership Appointments to Strengthen Executive Team for Next Phase of Growth
Cardiff Oncology has appointed Mani Mohindru as President and CEO, following her interim role. The company also welcomed Josh Muntner as CFO and Ajay Aggarwal as COO. These appointments aim to enhance leadership as Cardiff advances its lead asset, onvansertib, in treating RAS-mutant metastatic colorectal cancer. The new team is expected to drive the company's strategic priorities forward.
Read more →CRDFCardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer
Cardiff Oncology will host a key opinion leader webinar on March 25, 2026, focusing on first-line RAS-mutated metastatic colorectal cancer. The webinar will feature experts Scott Kopetz and Heinz-Josef Lenz discussing the clinical data of onvansertib, a PLK1 inhibitor. This event aims to shed light on emerging treatment strategies for this patient population.
Read more →CRDFCardiff Oncology to Present Preclinical Data with Highly Specific PLK1 Inhibitor Onvansertib at the 2026 AACR Annual Meeting
Cardiff Oncology announced the upcoming presentation of preclinical data on its oral PLK1 inhibitor, onvansertib, at the AACR Annual Meeting 2026. The research highlights onvansertib's ability to enhance the effectiveness of trastuzumab deruxtecan in HER2-low breast cancer models. This presentation underscores the drug's potential in overcoming therapy resistance and its role in various cancers including RAS-mutated colorectal cancer. The findings will be available on the company's website following the event.
Read more →CRDFCardiff Oncology to Participate in Three Upcoming Investor Conferences
Cardiff Oncology, Inc. (CRDF) announced participation in three investor conferences scheduled for March 2026. These include the TD Cowen 46th Annual Health Care Conference, the Barclays 28th Annual Global Healthcare Conference, and the Leerink Partners Global Healthcare Conference 2026. The company is known for its focus on PLK1 inhibition as a strategy to develop novel therapies for various cancers, highlighting its lead asset, onvansertib, currently evaluated in a Phase 2 trial. Interested parties can access conference webcasts via the Cardiff Oncology website.
Read more →CRDF▲ +12.4%on this newsshared move
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update
Cardiff Oncology reported positive results from its Phase 2 CRDF-004 trial for first-line RAS-mutated metastatic colorectal cancer, showing a 72.2% overall response rate. The company plans to advance the 30 mg dose of onvansertib into a registrational program, with detailed data expected in the first half of 2026. Financially, Cardiff has a strong cash position to support operations into 2027.
Read more →About Cardiff Oncology, Inc.
Headquarters11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121
BIOPHARMAWATCH ELITE PLUS
Trade the next CRDF catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime